Stemgent completes acquisition of Asterand’s human tissue business

Wednesday, August 1, 2012 11:03 AM

Stemgent, a Cambridge, Mass.-based developer of proprietary tools and services focused on the application of human cells, has completed the acquisition of Asterand’s human tissue business for $9 million.

Asterand provides a set of high quality, human-tissue based tools for drug and drug target discovery that is complementary to Stemgent’s growing portfolio of research products and services to advance cellular reprogramming and stem cell research.

“The Asterand acquisition is an important step in our efforts to build a significant research tools business focused on human cells,” said Ian Ratcliffe, president and CEO of Stemgent. “Asterand’s offerings, supply chain and customer base among pharmaceutical, biotechnology and diagnostic companies, along with Stemgent’s position in the academic research market and expertise developing stem cell research products, present multiple opportunities for growth.”

Asterand’s human tissue business includes the XpressBANK biobank and related services and PhaseZERO human tissue-based drug discovery research services. The biobank contains several hundred thousand consented, well characterized human tissue specimens that are linked to clinical information across a range of therapeutic areas. The unit also provides custom services such as isolation of specific cell lines and primary cells, tissue microarrays and biofluids, including blood serum and plasma. The PhaseZERO platform capitalizes on the biobank and includes human gene expression profiling in diseased and non-diseased tissue; human protein expression profiling; and human tissue-based primary cell assays for metabolism and toxicity analysis.

The human tissue and services operations will continue under the Asterand name. The combined organizations will have 100 employees with operations in the U.S. and U.K. Stemgent plans to retain Asterand’s operations in Detroit, Mich., and Royston, U.K.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs